Thromb Haemost 2001; 85(01): 18-21
DOI: 10.1055/s-0037-1612657
Rapid Communications
Schattauer GmbH

Circulating Procoagulant Microparticles in Women with Unexplained Pregnancy Loss: a New Insight

I. Laude
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
,
C. Rongières-Bertrand
3   Service de Gynécologie-Obstétrique, Hôpital Antoine-Béclère, AP-HP, Clamart
,
C. Boyer-Neumann
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
2   Service d’Hématologie Biologique
,
M. Wolf
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
2   Service d’Hématologie Biologique
,
V. Mairovitz
3   Service de Gynécologie-Obstétrique, Hôpital Antoine-Béclère, AP-HP, Clamart
,
B. Hugel
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
2   Service d’Hématologie Biologique
,
J. M. Freyssinet
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
4   Institut d’Hématologie et d’Immunologie, Faculté de Médecine, Strasbourg, France
,
R. Frydman
3   Service de Gynécologie-Obstétrique, Hôpital Antoine-Béclère, AP-HP, Clamart
,
D. Meyer
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
2   Service d’Hématologie Biologique
,
V. Eschwège
1   Unité 143 Institut National de la Santé et de la Recherche Médicale, Hôpital de Bicêtre, Le Kremlin-Bicêtre
› Author Affiliations
Further Information

Publication History

Received 12 May 2000

Accepted after revision 03 August 2000

Publication Date:
08 December 2017 (online)

Summary

One of the frequently proposed mechanisms for pregnancy losses refers to uteroplacental thrombosis. However the contribution of classical thrombotic risk factors remains questionable and, if real, does not account for a large number of pregnancy losses. The aim of this study was to investigate the presence of circulating procoagulant microparticles, a new marker of cell activation already associated with various prothrombotic clinical settings. Microparticles were assessed by an original prothrombinase assay on platelet depleted plasma obtained from 74 women with a history of pregnancy loss without apparent cause and 50 controls. Patients were studied at least 2 months after the last obstetrical event and were classified into 2 groups: 49 women with at least 3 consecutive spontaneous abortions at or before the 10th postmenstrual week and 25 with at least one fetal death beyond the 10th postmenstrual week. Among the 74 patients, 41 had increased levels of circulating microparticles, 29 belonging to the group of early pregnancy loss (59%) and 12 to the group of late pregnancy loss (48%). The high prevalence of increased levels of procoagulant microparticles in both groups makes this new marker very promising for the understanding, follow up and therapeutical handling of pregnancy loss.

 
  • References

  • 1 Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999; 14: 2868-71.
  • 2 Stirrat GM. Recurrent miscarriage I: Definition and epidemiology. Lancet 1990; 336: 673-5.
  • 3 Quenby SM, Farquharson RG. Predicting recurring miscarriage: what is important?. Obstet Gynecol 1993; 82: 132-8.
  • 4 Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, Daynes RA. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210-6.
  • 5 Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41: 179-86.
  • 6 Piona A, La Rosa L, Tincani A, Faden D, Magro G, Grasso S, Nicoletti F, Balestrieri G, Meroni PL. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand J Immunol 1995; 41: 427-32.
  • 7 Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, Harpel PC. Pregnancy loss in the antiphospholipid-antibody syndrome – a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154-60.
  • 8 Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
  • 9 Gris JC, Quéré I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, Hoffet M, Berlan J, Daures JP, Mares P. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent – the Nîmes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost 1999; 81: 891-9.
  • 10 Kupferminc M, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing J. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
  • 11 Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemost 1999; 82: 634-40.
  • 12 Warkentin TE, Hayward CPM, Boschkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
  • 13 Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996; 75: 427-31.
  • 14 Hugel B, Socié G, Vu T, Toti F, Gluckman E, Freyssinet JM, Scrobohaci ML. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
  • 15 Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
  • 16 Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96: 2311-5.
  • 17 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
  • 18 Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266: 17261-8.
  • 19 Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, Dainiak N. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 1998; 91: 3862-74.
  • 20 Barry OP, Pratico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-27.
  • 21 Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161: 4382-7.
  • 22 Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999; 274: 23111-8.
  • 23 Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, Freyssinet JM. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99: 1546-54.
  • 24 Gris JC, Ripart-Neveu S, Maugard C, Tailland ML, Brun S, Courtieu C, Biron C, Hoffet M, Hedon B, Marès P. Prospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nîmes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997; 77: 1096-103.
  • 25 Lockshin MD. Pregnancy loss and antiphospholipid antibodies. Lupus 1998; 7: S86-9.
  • 26 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
  • 27 Dachary-Prigent J, Pasquet JM, Freyssinet JM, Nurden AT. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: A study using Ca2+-ATPase inhibitors. Biochemistry 1995; 34: 11625-34.
  • 28 Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwège V, Hedman H, Freyssinet JM. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245-55.
  • 29 Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-14.
  • 30 Sugimura M, Kobayashi T, Shu F, Kanayama N, Terao T. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice. Placenta 1999; 20: 555-60.
  • 31 Wang X, Campos B, Kaetzel MA, Dedman JR. Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol 1999; 180: 1008-16.
  • 32 Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, Lockwood CJ. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566-72.
  • 33 Fourcade O, Simon MF, Viode C, Rugani N, Leballe F, Ragab A, Fournie B, Sarda L, Chap H. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995; 80: 919-27.